We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Millipore Corporation Signs License Agreement with Bayer HealthCare AG
News

Millipore Corporation Signs License Agreement with Bayer HealthCare AG

Millipore Corporation Signs License Agreement with Bayer HealthCare AG
News

Millipore Corporation Signs License Agreement with Bayer HealthCare AG

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Millipore Corporation Signs License Agreement with Bayer HealthCare AG"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Millipore Corporation has announced that it has entered into a worldwide, non-exclusive license agreement with Bayer HealthCare AG, a subsidiary of Bayer AG, to use Millipore’s UCOE™ (Ubiquitous Chromatin Opening Element) technology to manufacture its biologic drugs.

The license will enable Bayer to efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations. Financial terms were not disclosed.

The process of manufacturing biologic drugs such as recombinant proteins often begins with growing mammalian cells in a bioreactor. These cells act as “factories” and produce the proteins that form the basis of biologic drugs. Millipore’s UCOE technology helps biopharmaceutical companies to identify which cells will be the most effective in producing proteins during large-scale manufacturing.

“We have built successful relationship with Bayer over a number of years, and we are excited about their commitment to the UCOE technology,” said Andrew Bulpin, Ph.D., Vice President of Millipore’s Upstream Bioprocessing Business Unit. “This license is another example of how we can help pharmaceutical and biotech companies efficiently manufacture biologic drugs for both commercial use and for use in clinical development.

Advertisement